Cost-Effectiveness Results of CT and CT + PET in Management of Metachronous Liver Metastases
| Strategy | Cost (€ [$]) | Life expectancy* (y) | Incremental cost-effectiveness ratio |
|---|---|---|---|
| CT + PET | 17,064 (20,526) | 1.88 | — |
| CT | 19,735 (23,739) | 1.88 | Dominated |
↵* All life expectancies were rounded up to 2 decimal places.
PET = 18F-FDG PET.